Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors

Mesenchymal stem cells from different sources and their derived exosomes: A pre-clinical perspective

(2020) María Álvarez-Viejo   World Journal of Stem Cells

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances

(2020) Cosimo Cumbo et al.   Cancer Management and Research

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors

(2020) Jee Hyun Kong et al.   Journal of Clinical Medicine

Exosomal transfer of LCP1 promotes osteosarcoma cell tumorigenesis and metastasis by activating the JAK2/STAT3 signaling pathway

(2020) Xuhui Ge et al.   Molecular Therapy-Nucleic Acids

Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options

(2019) Daniel Nisakar Meenakshi Sundaram et al.   DRUG DISCOVERY TODAY

Extracellular Vesicles–Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation

(2019) Silvia Baldari et al.   Cells

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

(2018) Masaya Okada et al.   Clinical Lymphoma Myeloma & Leukemia

Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway

(2018) Ying Liu et al.   CYTOTHERAPY

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

(2018) Oliver Ottmann et al.   Blood Cancer Journal

Molecular screening and the clinical impacts of BCR‑ABL KD mutations in patients with imatinib‑resistant chronic myeloid leukemia

(2017) Bet�l Ko�kan et al.   Oncology Letters

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma

(2016) Yanjie Li et al.   LEUKEMIA RESEARCH

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

(2016) Jean Claude Chomel et al.   Oncotarget

Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Angiogenesis: Potencial Clinical Application

(2016) Consuelo Merino-González et al.   Frontiers in Physiology

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

(2015) Koji Sasaki et al.   CANCER

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

(2015) T P Hughes et al.   LEUKEMIA

Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway

(2014) X. Li et al.   ARCHIVES OF TOXICOLOGY

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells

(2014) J. Wang et al.   BLOOD

Bone Marrow Mesenchymal Stem Cell-Derived Microvesicles Protect Rat Pheochromocytoma PC12 Cells from Glutamate-Induced Injury via a PI3K/Akt Dependent Pathway

(2014) Shan-Shan Lin et al.   NEUROCHEMICAL RESEARCH

Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells

(2014) M. Ono et al.   Science Signaling

New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia

(2014) Saeid Shahrabi et al.   TUMOR BIOLOGY

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling

(2013) B. Zhang et al.   BLOOD

BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

(2013) Aldo M. Roccaro et al.   JOURNAL OF CLINICAL INVESTIGATION

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

(2013) Concetta Quintarelli et al.   LEUKEMIA RESEARCH

Microvesicles Derived from Human Umbilical Cord Wharton’s Jelly Mesenchymal Stem Cells Attenuate Bladder Tumor Cell Growth In Vitro and In Vivo

(2013) Shuai Wu et al.   PLoS One

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

(2012) Bin Zhang et al.   CANCER CELL

Microvesicles Derived from Human Bone Marrow Mesenchymal Stem Cells Inhibit Tumor Growth

(2012) Stefania Bruno et al.   STEM CELLS AND DEVELOPMENT

Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo

(2011) Wei Zhu et al.   CANCER LETTERS

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

(2011) L F Peterson et al.   LEUKEMIA

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts

(2011) Y Tabe et al.   LEUKEMIA

MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib

(2011) M. Albajar et al.   MOLECULAR CANCER RESEARCH

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML

(2010) Rajesh R. Nair et al.   BIOCHEMICAL PHARMACOLOGY

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

(2010) F. Vianello et al.   HAEMATOLOGICA